Marinomed Biotech AG

Marinomed Biotech AG is a biopharmaceutical company. It specializes in the development of innovative products based on patent-protected technology platforms in the field of respiratory and ophthalmic diseases. Marinomed has received multiple prestigious research awards for its activities.

Marinomed has developed two platforms to date: the Marinosolv® technology platform and the Carragelose® platform.

The Marinosolv® technology platform enhances the efficacy of hardly soluble compounds. This innovative technology has the potential to sustainably change a number of therapies for allergies and auto-immune diseases. The flagship product Budesolv is currently being investigated in a pivotal Phase III approval study.

The Carragelose® platform is already used in six different products to treat viral infections of the respiratory tract, which are sold globally via the company’s partners.